Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Invested Capital (2016 - 2025)

Viking Therapeutics' Invested Capital history spans 12 years, with the latest figure at $639.1 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 27.4% year-over-year to $639.1 million; the TTM value through Dec 2025 reached $639.1 million, down 27.4%, while the annual FY2025 figure was $639.1 million, 27.4% down from the prior year.
  • Invested Capital for Q4 2025 was $639.1 million at Viking Therapeutics, down from $713.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $933.9 million in Q1 2024 and bottomed at $134.1 million in Q1 2023.
  • The 5-year median for Invested Capital is $358.3 million (2023), against an average of $470.0 million.
  • The largest annual shift saw Invested Capital decreased 29.01% in 2022 before it soared 596.6% in 2024.
  • A 5-year view of Invested Capital shows it stood at $201.9 million in 2021, then fell by 28.02% to $145.3 million in 2022, then soared by 139.76% to $348.4 million in 2023, then soared by 152.65% to $880.3 million in 2024, then fell by 27.4% to $639.1 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Invested Capital are $639.1 million (Q4 2025), $713.0 million (Q3 2025), and $795.5 million (Q2 2025).